Korean Red Ginseng and Ginsenoside-Rb1/-Rg1 Alleviate Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells and Upregulating Regulatory T Cells

被引:0
作者
Min Jung Lee
Minhee Jang
Jonghee Choi
Byung Soo Chang
Do Young Kim
Sung-Hoon Kim
Yi-Seong Kwak
Seikwan Oh
Jong-Hwan Lee
Byung-Joon Chang
Seung-Yeol Nah
Ik-Hyun Cho
机构
[1] College of Korean Medicine,Department of Cancer Preventive Material Development
[2] Kyung Hee University,Department of Convergence Medical Sciences, College of Korean Medicine
[3] Kyung Hee University,Institute of Korean Medicine
[4] Kyung Hee University,Department of Cosmetology
[5] Hanseo University,Central Research Institute
[6] Barrow Neurological Institute and St. Joseph’s Medical Center,Department of Neuroscience and Tissue Injury Defense Research Center, School of Medicine
[7] Korea Ginseng Corporation,Department of Veterinary Anatomy, College of Veterinary Medicine
[8] Ewha Womans University,Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine and Bio/Molecular Informatics Center
[9] Konkuk University,undefined
[10] Konkuk University,undefined
[11] Brain Korea 21 Plus Program,undefined
[12] Kyung Hee University,undefined
来源
Molecular Neurobiology | 2016年 / 53卷
关键词
Korean red ginseng; Ginsenosides; Experimental autoimmune encephalomyelitis; T cell;
D O I
暂无
中图分类号
学科分类号
摘要
The effects of Korean red ginseng extract (KRGE) on autoimmune disorders of the nervous system are not clear. We investigated whether KRGE has a beneficial effect on acute and chronic experimental autoimmune encephalomyelitis (EAE). Pretreatment (daily from 10 days before immunization with myelin basic protein peptide) with KRGE significantly attenuated clinical signs and loss of body weight and was associated with the suppression of spinal demyelination and glial activation in acute EAE rats, while onset treatment (daily after the appearance of clinical symptoms) did not. The suppressive effect of KRGE corresponded to the messenger RNA (mRNA) expression of proinflammatory cytokines (tumor necrosis factor-α [TNF-α] and interleukin [IL]-1β), chemokines (RANTES, monocyte chemotactic protein-1 [MCP-1], and macrophage inflammatory protein-1α [MIP-1α]), adhesion molecules (intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1], and platelet endothelial cell adhesion molecule [PECAM-1]), and inducible nitric oxide synthase in the spinal cord after immunization. Interestingly, in acute EAE rats, pretreatment with KRGE significantly reduced the population of CD4+, CD4+/IFN-γ+, and CD4+/IL-17+ T cells in the spinal cord and lymph nodes, corresponding to the downregulation of mRNA expression of IFN-γ, IL-17, and IL-23 in the spinal cord. On the other hand, KRGE pretreatment increased the population of CD4+/Foxp3+ T cells in the spinal cord and lymph nodes of these rats, corresponding to the upregulation of mRNA expression of Foxp3 in the spinal cord. Interestingly, intrathecal pretreatment of rats with ginsenosides (Rg1 and Rb1) significantly decreased behavioral impairment. These results strongly indicate that KRGE has a beneficial effect on the development and progression of EAE by suppressing T helper 1 (Th1) and Th17 T cells and upregulating regulatory T cells. Additionally, pre- and onset treatment with KRGE alleviated neurological impairment of myelin oligodendrocyte glycoprotein35–55-induced mouse model of chronic EAE. These results warrant further investigation of KRGE as preventive or therapeutic strategies for autoimmune disorders, such as multiple sclerosis.
引用
收藏
页码:1977 / 2002
页数:25
相关论文
共 334 条
[1]  
Lassmann H(2011)The molecular basis of neurodegeneration in multiple sclerosis FEBS Lett 585 3715-3723
[2]  
van Horssen J(2007)Multiple sclerosis: a complicated picture of autoimmunity Nat Immunol 8 913-919
[3]  
McFarland HF(1993)Multiple sclerosis: genetic background versus environment Ann Neurol 34 509-510
[4]  
Martin R(2007)Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain J Exp Med 204 2899-2912
[5]  
Ragheb S(2012)Capture, crawl, cross: the T cell code to breach the blood–brain barriers Trends Immunol 33 579-589
[6]  
Lisak R(2012)Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis Clin Dev Immunol 2012 970789-461
[7]  
Serafini B(2012)Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies Pharmacogenomics J 12 453-554
[8]  
Rosicarelli B(1996)Side effect profile of interferon beta-1b in MS: results of an open label trial Neurology 46 552-S183
[9]  
Franciotta D(2009)New oral drugs for multiple sclerosis Neurol Sci 30 S179-353
[10]  
Magliozzi R(2013)Current and future therapies for multiple sclerosis Scientifica 2013 249101-761